Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma

Trial Status: administratively complete

This pilot phase I trial studies the side effects and how well HLA-A2-restricted synthetic glioma antigen peptides vaccine and poly ICLC work in treating children with newly diagnosed high-grade glioma, brainstem glioma or low-grade glioma that has come back and can’t be removed by surgery. Vaccines made from small proteins called peptides may help the body build an effective immune response to kill tumor cells that express these glioma-associated peptides. Synthetic ribonucleic acids like poly ICLC may improve the effects of the vaccine. Giving HLA-A2-restricted synthetic glioma antigen peptides vaccine with poly ICLC may kill more tumor cells.